207 related articles for article (PubMed ID: 20113333)
1. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
2. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
3. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status.
Heller PG; Lev PR; Salim JP; Kornblihtt LI; Goette NP; Chazarreta CD; Glembotsky AC; Vassallu PS; Marta RF; Molinas FC
Eur J Haematol; 2006 Sep; 77(3):210-6. PubMed ID: 16923108
[TBL] [Abstract][Full Text] [Related]
4. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia.
Li J; Xia Y; Kuter DJ
Br J Haematol; 2000 Dec; 111(3):943-53. PubMed ID: 11122159
[TBL] [Abstract][Full Text] [Related]
5. Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia.
Randi ML; Putti MC; Pacquola E; Luzzatto G; Zanesco L; Fabris F
Pediatr Blood Cancer; 2005 Jan; 44(1):47-50. PubMed ID: 15390356
[TBL] [Abstract][Full Text] [Related]
6. Detection of MPL mutations by a novel allele-specific PCR-based strategy.
Furtado LV; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2013 Nov; 15(6):810-8. PubMed ID: 23994117
[TBL] [Abstract][Full Text] [Related]
7. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.
Taksin AL; Couedic JP; Dusanter-Fourt I; Massé A; Giraudier S; Katz A; Wendling F; Vainchenker W; Casadevall N; Debili N
Blood; 1999 Jan; 93(1):125-39. PubMed ID: 9864154
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
9. MPLW515L mutation in acute megakaryoblastic leukaemia.
Hussein K; Bock O; Theophile K; Schulz-Bischof K; Porwit A; Schlue J; Jonigk D; Kreipe H
Leukemia; 2009 May; 23(5):852-5. PubMed ID: 19194467
[TBL] [Abstract][Full Text] [Related]
10. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
11. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S; Conneally E; Langabeer SE
Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
[No Abstract] [Full Text] [Related]
12. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
[TBL] [Abstract][Full Text] [Related]
13. Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity.
Abbà C; Campanelli R; Catarsi P; Villani L; Abbonante V; Sesta MA; Barosi G; Rosti V; Massa M
PLoS One; 2019; 14(8):e0220189. PubMed ID: 31369569
[TBL] [Abstract][Full Text] [Related]
14. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
[TBL] [Abstract][Full Text] [Related]
15. Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines.
Dillon M; Minear J; Johnson J; Lannutti BJ
Leuk Res; 2008 May; 32(5):811-9. PubMed ID: 17980909
[TBL] [Abstract][Full Text] [Related]
16. A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia.
Griesshammer M; Bangerter M; Schrezenmeier H
Semin Thromb Hemost; 1997; 23(5):419-23. PubMed ID: 9387200
[TBL] [Abstract][Full Text] [Related]
17. A novel thrombopoietin signaling defect in polycythemia vera platelets.
Moliterno AR; Siebel KE; Sun AY; Hankins WD; Spivak JL
Stem Cells; 1998; 16 Suppl 2():185-92. PubMed ID: 11012190
[TBL] [Abstract][Full Text] [Related]
18. Activation of Janus kinase/signal transducers and activators of transcription pathway involved in megakaryocyte proliferation induced by vanadium resembles some aspects of essential thrombocythemia.
Gonzalez-Villalva A; Piñon-Zarate G; Falcon-Rodriguez C; Lopez-Valdez N; Bizarro-Nevares P; Rojas-Lemus M; Rendon-Huerta E; Colin-Barenque L; Fortoul TI
Toxicol Ind Health; 2016 May; 32(5):908-18. PubMed ID: 24442345
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
